Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P561: Impact of ustekinumab TDM on clinical practice: a multi-centre, prospective, cross-sectional observational trial—mUST-Decide

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Bressler*1, D. Dajnowiec2, M. Williamson3, K. Karra3, G. Long-Long4, B. Sattin3, W. Afif5

1University of British Columbia, Vancouver, Canada, 2Janssen Inc., Medical Affairs, Canada, Canada, 3Janssen Inc., Medical Affairs, Toronto, Canada, 4Janssen Inc., Research and Development, LLC, Spring House, USA, 5McGill University, Montreal, Canada

P562: Treatment of older inflammatory bowel disease patients; steroid use and escalation to steroid sparing therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Asscher*1, N. Provoost1, L. Meijer1, A. van der Meulen-de Jong1, F. van Deudekom2, S. Mooijaart2,3, J. Maljaars1

1LUMC, Gastroenterology and Hepatology, Leiden, The Netherlands, 2LUMC, Gerontology and Geriatrics, Leiden, The Netherlands, 3Institute for Evidence-Based Medicine in Old Age (IEMO), Leiden, The Netherlands

P563: Thiopurine adverse events in patients with inflammatory bowel disease in the UK: inflammatory bowel disease BioResource cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

Y. Y. Hong*1, D. A. Withanachchi1, S. P. Aslam1, Y. Khalid1, R. Shawky1, M. Parkes1

1Gastroenterology Department, Addenbrooke's Hospital, Cambridge, UK

P564: Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Hoefkens*1, L. Pouillon1, V. Verheyen2, M. Bronswijk1, A. Van Olmen1, S. Van Dessel3, N. Siborgs4, P. Bossuyt1,5

1Imelda general hospital, Department of gastroenterology, Bonheiden, Belgium, 2Imelda general hospital, Central hospital pharmacy, Bonheiden, Belgium, 3Imelda general hospital, IBD infusion unit, Bonheiden, Belgium, 4Imelda general hospital, IT department, Bonheiden, Belgium, 5University Hospitals Leuven, Catholic University of Leuven, Department of gastroenterology and hepatology, Leuven, Belgium

P565: Infliximab therapy intensification upon loss of response: what should be the cut-off for trough levels?

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Ungar*1, Z. Ben-Shatach1, G. Ben-Haim1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, É. Del Tedesco2, P. Veyrard2, P. Stephane2, R. Eliaklim1, S. Ben-Horin1, X. Roblin2

1Gastroenterology Sheba Medical Center, Ramat Gan, Israel, 2Gastroenterology unit, University hospital of Saint Etienne, Saint-Priest-en-Jarez, France

P566: The cost for IBD care during the first 5 years after diagnosis

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Sjöberg*1, U. Karlbom2, M. Thörn3, D. Fawunmi4, A. Rönnblom3

1Centre of Clinical Research, Falun, Sweden, 2Uppsala University Hospital, Department of Surgical Sciences, Uppsala, Sweden, 3Uppsala University Hospital, Department of Gastroenterology, Uppsala, Sweden, 4Mälarsjukhuset, Medical clinic, Eskilstuna, Sweden

P567: Could an escalation of therapy or intervention (ETI) calculator be used to triage appointments for patients with ulcerative colitis?

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Walsh*1, L. Matini1, R. Kantschuster1, M. Lepetyukh1, R. Nedescu1, J. Wilson1, O. Brain1, R. Palmer1, S. Keshav1, S. Travis1

1John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, UK

P568: Bowel ultrasonography is useful to evaluate disease activity in ulcerative colitis patients

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Takahashi*1, Y. Hirano1, K. Izumikawa1, H. Colvin1, M. Colvin1, T. Kagawa1, Y. Aoyama1, M. Matsueda1, Y. Kawai1, K. Okamoto1, I. Sakakihara1, K. Yamamoto1, S. Tanaka1, M. Matsuura1, S. Ishikawa1, M. Wato1, T. Hasui1, T. Inaba1

1Kagawa Prefectural Central Hospital, Department of Gastroenterological Surgery, Takamatsu, Japan

P569: A national, retrospective, observational study on the use of 5-aminosalicylates (5-ASA) in Crohn’s disease (CD)

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Hart1, S. C. Ng2, S. Ghosh3, J. Watkins4,5, J. Fullarton6, K. Paridaens*7

1St Mark's Hospital, Harrow, UK, 2The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, Hong Kong, 3University of Birmingham, Birmingham, UK, 4Public Health Wales, Cardiff, UK, 5University of Cardiff, Cardiff, UK, 6Strategen Limited, Basingstoke, UK, 7Ferring International Center, St-Prex, Switzerland

P570: Kock pouches in the 21st century: a descriptive study of short-term (30-day) outcomes in a national cohort of 177 patients

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Shawki1, S. Steele1, J. Lipman1, C. H. A. Lee1, L. Stocchi1, T. Hull1, E. Gorgun1, S. Holubar*1

1Cleveland Clinic, Colon and Rectal Surgery, Cleveland, USA

P571: Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Bar-Gil Shitrit1, M. Siterman2, M. Waterman3, A. Hirsh4, T. Khoury5, D. Schwartz6, E. Zittan7, J. Adler8, B. Koslowsky1, I. Avni-Biron2, Y. Chowers3, Y. Ron4, E. Israeli5, B. Ungar8, H. Yanai2, N. Maharshak4, S. Ben-Horin8, A. Ben-Ya'acov1, R. Eliakim8, I. Dotan2, E. Goldin1, U. Kopylov8

1Shaare Zedek Medical Center, affiliated with the Faculty of Medicine, Hebrew University, Jerusalem, Israel, Digestive Diseases Institute, Jerusalem, Israel, 2Rabin Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Division of Gastroenterology, Petah Tikwa, Israel, 3Rambam Health Care Campus, Affiliated with the Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel, Department of Gastroenterology, Haifa, Israel, 4Tel Aviv Sourasky Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 5Hebrew University Hadassah Medical Center, Institute of Gastroenterology, Jerusalem, Israel, 6Soroka Medical Center, Affiliated with the Faculty of Medicine, Beer Sheba University, Beer Sheba, Israel, Department of Gastroenterology, Beer Sheva, Israel, 7Haemek Medical Center, Affiliated with the Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel, Department of Gastroenterology, Afula, Israel, 8Sheba Medical Center, Tel Hashomer, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Department of Gastroenterology, Tel Hashomer, Israel

P572: Half of children with acute severe colitis have predominant single faecal bacterial species, mostly Escherichia coli: Microbiome results from the PRASCO trial

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Bishai1, G. Abitbol2, G. Focht2, M. Schirmer1, D. Marcus2, B. Yerushalmi3, M. Aloi4, A. M. Griffiths5, L. Albenberg1, K-L. Kolho6, S. Cohen7, A. Assa8, A. Levine9, H. Vlamakis1, R. Xavier1, D. Turner*2

1The Broad Institute of MIT and Harvard, Center for Computational and Integrative Biology, Boston, USA, 2Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 3Faculty of Health Sciences, Ben-Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 4Sapienza University of Rome, Rome, Italy, 5The Hospital for Sick Children (SickKids), Toronto, Canada, 6Hospital for Children and Adolescents, Children′s Hospital, Helsinki University, Helsinki, Finland, 7Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 8Schneider Children's Medical Center, Petach Tiqua, Israel, 9Wolfson Medical Center, Holon, Israel

P573: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Yarur*1, G. Mantzaris2, M. Silverberg3, M. Walshe3, P. Zezos3, D. Stein4, M. Bassel5, T. Lissoos6, C. Lopez6, A. Natsios7, G. Radulescu8, H. Patel9, D. Demuth10, B. Bressler11

1Medical College of Wisconsin, Milwaukee, USA, 2Evangelismos Hospital, Athens, Greece, 3IBD Center, Mount Sinai Hospital, Toronto, Canada, 4Evidera, London, UK, 5Evidera, Montreal, Canada, 6Takeda USA Inc., Chicago, USA, 7Takeda SA Inc., Athens, Greece, 8Takeda Canada Inc., Toronto, Canada, 9Takeda Pharmaceuticals International, Deerfield, USA, 10Takeda International - UK Branch, London, UK, 11St. Paul's Hospital, Vancouver, Canada

P574: IBD patients should be stratified to guide out-of-hospital monitoring: ICHOM-derived outcomes from a dedicated IBD telephone clinic

ECCO '19 Copenhagen

Year: 2019
Authors:

R. K. Fofaria*1, S. Azana1, G. Grande1, P. Naeck-Boolauky1, T. Tyrrell1, N. Arebi1

1St Mark's Hospital, IBD Department, London, UK

P575: Simple novel tacrolimus enemas are very effective in severe refractory proctitis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. R. Fehily*1, F. C. Martin1, M. A. Kamm1,2

1St Vincent's Hospital, Gastroenterology, Melbourne, Australia, 2University of Melbourne, Melbourne, Australia

P576: Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Bertani*1, G. Bodini2, G. Mondello1, M. G. Mumolo3, S. Maltinti1, I. Baldissarro2, G. Tapete1, E. Albano1, L. Ceccarelli3, M. Crespi2, V. Savarino2, S. Marchi1, F. Costa3

1University of Pisa, Department of new technologies and translational sciences in medicine and surgery, Pisa, Italy, 2University of Genoa, Department of Internal Medicine, Gastroenterology Unit, Genoa, Italy, 3Pisa University Hospital, Department of General Surgery and Gastroenterology, Pisa, Italy

P577: Drug Induced Liver Injury (DILI) secondary to biologic therapy in IBD: ECCO- CONFER Series

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Lisle1, S. Myers1, D. Pugliese2, T. Raine3, A. C. de Vries4, K. Katsanos5, R. Filip6, K. Karmiris7, S. Sebastian*1,8

1IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK, 2IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Rome, Italy, 3Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 4Erasmus Medical Centre, Rotterdam, The Netherlands, 5School of health sciences and University Hospital of Ioannina, Ioannina, Greece, 6IBD Unit, Rzeszow University, Rzeszow, Poland, 7Venizeleio General Hospital, Crete, Greece, 8Hull York Medical School, University of Hull and York, Hull, UK

P578: Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Santos*1, V. Gamelas2, D. Carvalho2, C. Bernardes2, J. Saiote2, J. Ramos2

1Centro Hospitalar Lisboa Central EPE, Gastroenterology, Lisboa, Portugal, 2Centro Hospitalar Lisboa Central, Lisboa, Portugal

P579: Wearable Devices Can Predict Disease Activity in inflammatory bowel disease Patients

ECCO '19 Copenhagen

Year: 2019
Authors:

P. H. Sossenheimer*1, O. V. Yvellez1, M. Andersen Jr1, T. Pearl1, K. El Jurdi1, D. B. Rubin1, A. Mayampurath2, D. T. Rubin1

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, USA, 2Litmus Health, Inc., Austin, TX, USA

P580: Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Picardo*1, R. Panaccione1, G. Kaplan1,2, C. Seow1,2, J. deBruyn3, Y. Leung1,4

1Univeristy of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada, 2University of Calgary, Community Health Sciences, Calgary, Canada, 3University of Calgary, Pediatric Gastroenterology, Calgary, Canada, 4University of British Columbia, Inflammatory Bowel Disease Unit, Vancouver, Canada